List of Excipients in Branded Drug UCERIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Salix Pharmaceuticals Inc	UCERIS	budesonide	65649-651	BUTANE
Salix Pharmaceuticals Inc	UCERIS	budesonide	65649-651	CETOSTEARYL ALCOHOL
Salix Pharmaceuticals Inc	UCERIS	budesonide	65649-651	CETYL ALCOHOL
Salix Pharmaceuticals Inc	UCERIS	budesonide	65649-651	CITRIC ACID MONOHYDRATE
Salix Pharmaceuticals Inc	UCERIS	budesonide	65649-651	EDETATE DISODIUM
Salix Pharmaceuticals Inc	UCERIS	budesonide	65649-651	ISOBUTANE

UCERIS Excipient Strategy and Commercial Opportunities for Budesonide Extended-Release Tablets

Last updated: August 21, 2026

UCERIS is a 9 mg oral extended-release budesonide tablet for induction of clinical remission in adults with mild to moderate ulcerative colitis. Its commercial differentiation depends less on the active ingredient than on site-specific delivery, release kinetics, dose reproducibility, and gastrointestinal tolerability. The strongest excipient opportunities are multipart coating systems, pH-triggered release, matrix control, moisture protection, and lower-cost alternatives to proprietary multimatrix technology.

The product’s main commercial vulnerability is that generic budesonide extended-release tablets can compete through the same active ingredient and therapeutic indication. A differentiated excipient platform could support new formulations, lifecycle extensions, pediatric products, lower-dose maintenance products, combination therapies, and regional licensing.

What is UCERIS and how does its formulation work?

UCERIS contains budesonide, a locally acting corticosteroid with high first-pass hepatic metabolism. The tablet is designed to release budesonide throughout the colon rather than primarily in the stomach or proximal small intestine.

UCERIS product profile

Attribute	UCERIS tablet
Active ingredient	Budesonide
Strength	9 mg
Dosage form	Oral extended-release tablet
Initial FDA approval	January 2013
Applicant at approval	Santarus, later acquired by Salix Pharmaceuticals
Current commercial affiliation	Bausch Health/Salix portfolio
Indication	Induction of remission in adults with mild to moderate ulcerative colitis
Administration	One tablet daily, generally for up to eight weeks
Delivery target	Colon
Regulatory pathway	New Drug Application 203634
Primary formulation value	Controlled, delayed and extended colonic release

The commercial technology is commonly associated with MMX, or multimatrix, delivery. MMX systems typically combine a tablet core containing the active ingredient with hydrophilic and lipophilic excipients, surrounded by a gastro-resistant coating. The coating protects the dosage form in the stomach and delays release until the tablet reaches a higher-pH intestinal environment. The matrix then controls dispersion and release through the colon.

The FDA-approved labeling identifies excipients including lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate and coating components used to provide delayed and extended release. Exact excipient composition and manufacturing parameters should be verified against the current approved labeling and CMC records before development or freedom-to-operate decisions.[1]

What excipients are used in UCERIS tablets?

UCERIS uses conventional pharmaceutical excipients in a nonconventional release architecture. The key commercial issue is not whether an excipient is individually novel. It is whether the combination creates reliable colonic delivery without infringing formulation or manufacturing claims.

Functional excipient categories

Excipient function	Likely role in UCERIS-type formulation	Commercial importance
Diluent	Provides tablet mass and compressibility	Controls cost, hardness and dose uniformity
Binder	Supports core integrity during coating and transit	Reduces premature erosion
Disintegrant or hydrophilic polymer	Controls water ingress and matrix swelling	Determines release rate
Lipophilic matrix material	Slows liquid penetration and drug diffusion	Extends colonic release
Lubricant	Supports compression and ejection	Excess can slow dissolution
Enteric polymer	Protects against gastric release	Determines pH-triggered opening
Plasticizer	Improves coating flexibility	Reduces cracking and dose dumping
Anti-tacking agent	Prevents coating adhesion	Supports efficient coating operations
Opacifier or colorant	Product identification and light protection	Supports brand and generic differentiation
Moisture barrier	Stabilizes polymer and drug product	Important for long-term storage

Lactose monohydrate and microcrystalline cellulose are commercially attractive because they are widely available and supported by extensive regulatory precedent. Their use can reduce supply risk and simplify generic development. They can also create limitations. Lactose may be unsuitable for some patients or markets requiring lactose-free labeling, while microcrystalline cellulose may produce different compaction and porosity profiles across suppliers.

Magnesium stearate concentration and blending time require close control. Over-lubrication can reduce tablet tensile strength, alter wetting, and delay release. Colloidal silicon dioxide can improve flow but may affect powder segregation and tablet weight variation if the formulation has a high proportion of fine particles.

What formulation patents protect UCERIS?

UCERIS protection is likely divided among composition, controlled-release, manufacturing and method-of-use rights. The exact enforceability of each claim depends on claim scope, prosecution history, terminal disclaimers, patent-term adjustment and litigation outcomes.

Relevant patent categories

Patent category	Potential protected subject matter	Competitive effect
Composition patent	Budesonide in a multimatrix or controlled-release tablet	Can constrain direct tablet copies
Release-profile patent	Delayed release followed by colonic extended release	Requires comparative dissolution and in vivo support
Coating patent	Enteric polymer systems and coating architecture	May create design-around opportunities
Manufacturing patent	Layering, granulation, compression or coating sequence	Can affect process selection
Method-of-use patent	Treatment of ulcerative colitis with specific dosing	Relevant to labeling and Paragraph IV risk
Pediatric or maintenance patent	Different age group, duration or dosing regimen	Supports lifecycle management

Publicly reported Orange Book records for UCERIS and budesonide extended-release tablets have included formulation and use-related patents. Patent numbers and listed expiration dates must be checked in the FDA Orange Book for the applicable edition because listings can change through delisting, expiration, patent-term adjustment or regulatory action.[2]

A product developer should separate three questions:

1. Whether an active patent is listed for the reference product.
2. Whether the proposed generic or follow-on formulation falls within the asserted claims.
3. Whether the applicant can certify Paragraph IV, use a section viii statement, or wait for patent expiry.

An excipient substitution alone does not guarantee freedom to operate. Claims may cover the dosage form, release profile, matrix architecture or manufacturing sequence rather than a named excipient.

When does UCERIS lose exclusivity?

UCERIS lost practical exclusivity when FDA-approved generic budesonide extended-release products entered or became commercially available. The timing of market entry depends on FDA approval, Paragraph IV litigation, settlement terms, authorized-generic decisions and manufacturing readiness.

Regulatory exclusivity

Exclusivity type	UCERIS relevance
New chemical entity exclusivity	Budesonide was not a new chemical entity at UCERIS approval
Orphan exclusivity	UCERIS was not approved as an orphan product for its core indication
Three-year clinical investigation exclusivity	May have applied to qualifying new clinical data, but it does not permanently block ANDA approval
Patent exclusivity	Depends on listed patents and litigation
Regulatory market exclusivity	Separate from patent term and may not prevent all approvals

UCERIS is therefore primarily a formulation and patent-estate product, not a long-lived new-molecule product. The commercial window depends on the ability to protect colonic delivery and preserve prescriber preference after generic entry.

Which companies are challenging UCERIS with generic products?

Generic competition has centered on budesonide extended-release tablets equivalent to the 9 mg UCERIS product. Public FDA approval records should be used to identify each approved applicant, approval date, therapeutic-equivalence code and commercial status.

The generic competitive set may include large ANDA manufacturers with experience in modified-release tablets, such as Viatris/Mylan and other companies active in gastrointestinal generics. Approval does not always mean immediate launch. Commercial entry can be delayed by patent settlements, manufacturing capacity, supply economics or a decision to market only selectively.

Generic product risks

Risk	Impact on UCERIS
AB-rated generic tablet	Direct price erosion and substitution
Authorized generic	Accelerates price pressure while retaining some sponsor economics
Multiple generic entrants	Rapid reduction in net price
Non-equivalent delivery system	May support brand differentiation if clinical or labeling differences exist
Pharmacy substitution	Reduces prescriber control over product choice
Payer formulary pressure	Increases step-editing and rebate demands

What excipient strategies can compete with UCERIS?

The most viable strategy is a platform that reproduces colonic targeting while reducing manufacturing cost or enabling a new clinical use. A direct copy based on the same release architecture faces the greatest patent and substitution pressure.

1. Alternative enteric polymer systems

A developer could use methacrylic acid copolymers, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate or other approved enteric polymers. The selection affects dissolution pH, coating weight, film strength, storage stability and geographic regulatory acceptance.

A polymer system that opens at a slightly different pH may create a design-around position, but it must still meet the intended colonic release profile. Excessively early release can expose budesonide in the small intestine. Excessively late release can reduce clinical performance.

2. Enzyme- or microbiota-responsive coatings

Polysaccharide coatings that respond to colonic bacteria can provide an alternative targeting mechanism. Candidate materials include amylose-rich systems, pectin, chitosan derivatives and other biodegradable polymers.

The principal development barriers are batch-to-batch variability in colonic microbiota, incomplete release in some patients, coating robustness and more complex in vitro-in vivo correlation. This approach may be better suited to a differentiated 505(b)(2) product than a conventional ANDA.

3. Hydrophilic-lipophilic matrix optimization

A matrix using combinations of hydrophilic polymers, waxes and lipid excipients can control drug diffusion and erosion after the enteric coat dissolves. Commercial opportunities include:

• Lower-cost direct-release alternatives to proprietary MMX systems.
• Smaller tablets with equivalent dose delivery.
• Reduced variability after fed and fasted administration.
• More consistent release in patients with altered intestinal transit.
• Modified release for lower-dose maintenance therapy.

The formulation must control dose dumping, tablet fracture and release changes caused by food, gastrointestinal pH and transit time.

4. Lactose-free and low-allergen products

A lactose-free UCERIS-type tablet could address patients who avoid lactose-containing products and may simplify positioning in certain markets. Mannitol, dibasic calcium phosphate, starch derivatives and additional grades of microcrystalline cellulose are potential diluent alternatives.

The substitution can change compactability, water uptake and coating adhesion. A lactose-free product would need full comparative dissolution, stability and bioequivalence support.

5. Low-dose and maintenance formulations

UCERIS is positioned primarily for induction. A 3 mg or 6 mg extended-release product could support tapering, maintenance or steroid-sparing protocols, subject to clinical and regulatory support.

This opportunity is commercially attractive because an induction-only product has a limited treatment duration. A lower-dose formulation could increase duration of therapy but would face safety, labeling and clinical-evidence requirements. It could also face method-of-use patents if the relevant claims cover maintenance dosing.

6. Pediatric formulations

Pediatric ulcerative colitis is a potential lifecycle market. Mini-tablets, multiparticulates, sprinkle capsules or granules could provide flexible dosing and easier administration than a 9 mg adult tablet.

Excipient priorities would include palatability, swallowability, dose flexibility, low alcohol content in coatings, and robust colonic targeting at smaller particle sizes. A pediatric formulation may qualify for regulatory incentives only if it satisfies applicable FDA requirements, and it should not be assumed to receive exclusivity without a qualifying development program.

How strong is the UCERIS patent estate?

The estate is strongest where claims combine the active ingredient with a defined colonic-release architecture and measurable dissolution or pharmacokinetic performance. It is weaker against formulations that use a materially different delivery mechanism and avoid limitations in the asserted claims.

Stronger protection indicators

• Claims covering the tablet as a whole rather than a single excipient.
• Defined release in the colon or a specified gastrointestinal region.
• Multiple independent formulation and manufacturing claims.
• Patent-term coverage extending beyond regulatory exclusivity.
• Successful defense against Paragraph IV litigation.
• Clinical or pharmacokinetic data linked to the claimed formulation.

Weaker protection indicators

• Narrow claims to commercially common excipients.
• Claims requiring a specific coating polymer that can be replaced.
• Dependence on a single manufacturing step.
• Expired or delisted Orange Book patents.
• Release-profile claims that can be avoided through an alternative mechanism.
• Lack of current commercial relevance after generic entry.

For a prospective licensee, the core diligence issue is claim mapping. The analysis should compare the proposed formulation against each independent claim, including coating composition, matrix composition, tablet geometry, dissolution windows and manufacturing steps.

What patent litigation and Paragraph IV issues affect UCERIS?

An ANDA applicant challenging a listed patent can submit a Paragraph IV certification alleging that the patent is invalid, unenforceable or not infringed. The reference sponsor may then bring litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[3]

A settlement can permit entry before patent expiry, authorize a generic, limit launch quantities, or establish a date linked to litigation outcomes. Settlement economics depend on the number of challengers and whether the first filer receives 180-day exclusivity.

The relevant commercial documents include:

• FDA Orange Book patent listings.
• ANDA Paragraph IV notices.
• District court complaints.
• Federal Circuit opinions.
• FDA approval letters.
• Settlement filings and antitrust disclosures.
• Product launch announcements.

No single patent date should be treated as the generic launch date without reviewing litigation and settlement records.

What manufacturing and IP barriers affect excipient commercialization?

The principal barrier is process reproducibility. A colonic-release tablet can pass a single dissolution test while failing under agitation, pH transition, storage or scale-up conditions.

Critical process parameters include:

• Granulation endpoint.
• Polymer distribution within the matrix.
• Compression force and tablet porosity.
• Coating weight gain.
• Spray rate and inlet temperature.
• Residual solvent and moisture.
• Coating curing time.
• Particle-size distribution.
• Lubrication time.
• Stability under high humidity.

Excipient suppliers can capture value by offering qualified polymer grades, technical packages, design-of-experiment support and regulatory change-control commitments. The strongest commercial position is usually a co-development relationship with a formulation developer rather than commodity excipient supply alone.

How does UCERIS compare with other budesonide delivery systems?

Product or technology	Delivery target	Main advantage	Main limitation
UCERIS tablet	Colon	Once-daily oral induction therapy	Formulation and patent complexity
Entocort EC	Ileum and proximal colon	Established controlled-release capsule	Different disease-location profile
Budesonide rectal foam	Distal colon and rectum	Local treatment for distal disease	Administration burden and limited reach
Budesonide enema	Rectum and colon	Direct local exposure	Patient acceptability
Conventional budesonide capsule	Variable intestinal release	Lower formulation complexity	Less precise colonic targeting
New multiparticulate system	Colon or selected regions	Flexible dosing and pediatric potential	Higher development and manufacturing burden

UCERIS competes on convenience and broad colonic delivery. Rectal products can be more effective for distal disease but are less convenient. Ileal-release products address a different anatomical target. A new excipient platform should therefore define its market by disease location, dosing duration and administration preference rather than by budesonide content alone.

What commercial opportunities exist for UCERIS-related excipients?

The highest-value opportunities are:

1. A non-infringing, lower-cost colonic-release tablet for generic or 505(b)(2) development.
2. A lactose-free or low-dose formulation with equivalent therapeutic targeting.
3. Pediatric mini-tablets or multiparticulates.
4. A maintenance-dose product that extends therapy beyond induction.
5. A coating platform adaptable to other locally acting gastrointestinal drugs.
6. A supplier-backed formulation package with regulatory-grade excipient documentation.
7. Regional licensing of MMX-like or alternative colonic-release technology.
8. Combination delivery systems pairing budesonide with a microbiome, anti-inflammatory or immunomodulatory agent.

Revenue exposure is concentrated in the first-line oral induction segment. Generic substitution can compress price quickly, while differentiated products can preserve value if they obtain separate labeling, demonstrate administration or tolerability advantages, or target populations underserved by the 9 mg adult tablet.

Key Takeaways

• UCERIS is a 9 mg once-daily extended-release budesonide tablet designed for colonic delivery.
• Its value lies in release architecture, not active-ingredient novelty.
• The relevant excipient strategy combines an enteric coating with a hydrophilic-lipophilic matrix.
• Generic entry creates substantial price and substitution risk.
• Excipient substitution does not automatically avoid formulation or process patents.
• The most attractive opportunities are lactose-free, lower-dose, pediatric, maintenance and alternative colon-targeted products.
• A new formulation is most defensible when it combines a distinct excipient architecture with a separate clinical or regulatory position.
• Manufacturing reproducibility, dissolution robustness and claim mapping are the central development issues.

FAQs About UCERIS Excipient and Formulation Opportunities

Can a UCERIS generic use different excipients?

Yes. An ANDA applicant can use different inactive ingredients if the formulation satisfies FDA requirements for safety, bioequivalence, pharmaceutical equivalence and performance. Different excipients do not eliminate infringement risk where patents claim the dosage form or release profile.

Is budesonide suitable for a 505(b)(2) formulation?

Potentially. A 505(b)(2) application may be appropriate for a materially different dosage form, strength, route, release mechanism or patient population supported by new data. The regulatory strategy depends on the extent of formulation and clinical difference from the reference product.

What excipient is most important for colonic targeting?

The enteric coating is often the most visible control point because it determines resistance to gastric conditions and the pH at which release begins. The matrix polymers are equally important after coating dissolution because they determine the duration and completeness of drug release.

Can a microbiota-triggered budesonide formulation replace UCERIS?

It could compete as a differentiated product, but it would need to demonstrate reliable release across patient variability and meet FDA requirements for its proposed pathway. Microbiota-triggered delivery is more likely to support a new product profile than a simple direct generic substitution.

Does UCERIS have biosimilar risk?

No. Budesonide is a small-molecule corticosteroid, so the relevant competition is generic or follow-on small-molecule competition under the Hatch-Waxman framework, not biosimilar competition under the Public Health Service Act.

References

1. U.S. Food and Drug Administration. (2024). UCERIS (budesonide) extended-release tablets prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certifications.
4. U.S. Food and Drug Administration. (2013). FDA approves Uceris for ulcerative colitis.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: UCERIS, NDA 203634.